BerGenBio to Participate in Investor Webcast and Q&A

- Artic Securities and Carnegie will host the event on Friday, June 2, 2023, at 11:00 a.m. CEST -


BERGEN, Norway, May 30, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the Company will participate in an investor webcast and Q&A session hosted by Arctic Securities and Carnegie on Friday, June 2, 2023, at 11:00 a.m. CEST.


Chief Executive Officer Martin Olin and Chief Financial Officer Rune Skeie are scheduled to attend and discuss BerGenBio’s clinical development program and the ongoing rights offering.


Investors may attend the event by contacting Arctic Securities by mail or Carnegie by mail


Presentation used in the webcast will be uploaded to the investor section of the Company’s website






Martin Olin CEO, BerGenBio ASA


Rune Skeie, CFO, BerGenBio ASA


About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.


BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit


Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.